Exelixis (EXEL) said a phase 3 study showed its cabozantinib drug reduced the risk of disease progression or death by 50% compared with placebo in patients with advanced gastrointestinal neuroendocrine tumors
The study involved 116 patients with median progression-free survival of 8.5 months with cabozantinib compared with 5.6 months with placebo, the company said Friday in a statement.
The results "demonstrate the benefits of cabozantinib across a wide range of patients with neuroendocrine tumors and further underscore the potential of cabozantinib to become a much-needed new option," Exelixis Chief Medical Officer Amy Peterson said in the statement.
The US Food and Drug Administration is currently reviewing a supplemental new drug application for cabozantinib, the company said.
Shares of Exelixis fell 5.2% in late Friday trading. Earlier, Oppenheimer downgraded the stock to perform from outperform and cut the price target to $33 from $41.
Price: 32.34, Change: -1.79, Percent Change: -5.24
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。